Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database

SIMPLE SUMMARY: The benefits of standard treatments in metastatic pancreatic cancer (mPC) in terms of overall survival (OS) remain to date unclear, especially after 70 years. Alongside geriatric and oncologic parameters, we showed that the gemcitabine + nab-paclitaxel regimen and anti-diabetic thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Catherine, Pamoukdjian, Frédéric, Aparicio, Thomas, Mebarki, Soraya, Poisson, Johanne, Manceau, Gilles, Taieb, Julien, Rance, Bastien, Katsahian, Sandrine, Charles-Nelson, Anaïs, Paillaud, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909682/
https://www.ncbi.nlm.nih.gov/pubmed/35267412
http://dx.doi.org/10.3390/cancers14051105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909682/
https://www.ncbi.nlm.nih.gov/pubmed/35267412
http://dx.doi.org/10.3390/cancers14051105

Ejemplares similares